Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Sawai to End Teribone Generic Sales following Patent Settlement
Sawai Pharmaceutical said on February 24 that it will discontinue sales of its generic version of Asahi Kasei Pharma’s osteoporosis drug Teribone (teriparatide), in line with a patent litigation settlement reached last year. The company announced the move on its…
To read the full story
Related Article
- Japan to Delist 387 Drugs from NHI Price List, Including Renivace
February 16, 2026
- Sawai, Asahi Kasei Reach Settlement in Teribone Patent Suit
October 22, 2025
- Sawai Ordered to Pay 3 Billion Yen in Damages in Teribone Suit, Set to Appeal
September 30, 2024
- Osaka Court Bars Sawai’s Teribone Generic over Manufacturing Patents
September 6, 2023
- Asahi Kasei Sues Sawai over Manufacturing Method of Teribone Generic
May 11, 2022
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…